Cell therapy for hematological and solid tumors
Cell engineering advancements, including base editing and dual antigen targeting, improve safety and efficacy across cancer types.
Novel approaches, such as in vivo chimeric antigen receptor (CAR)-T cell generation and CAR-macrophages aim to overcome current therapeutic limitations.
Allogeneic strategies and induced pluripotent stem cell-derived immune cells offer potential for off-the-shelf treatments, improving accessibility.
Metabolic and genetic reprogramming enhance cell function in hostile tumor environments, potentially expanding efficacy to solid tumors.
Combination strategies, particularly with checkpoint inhibitors, address challenges posed by the immunosuppressive tumor microenvironment.
Ongoing clinical trials of novel cell therapeutics show promising results across various cancer types, paving the way for future translational efforts.
Future directions incorporate advanced gene editing, synthetic biology, and artificial intelligence-driven approaches to create more targeted and controllable immune effector cells.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(24)00226-8
